Analysis of site performance in academic-based and community-based centers in the IDEAL Study.


Journal Article

To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study.In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study, the participation of 76 academic-based and 42 community-based US centers provided an opportunity to evaluate various metrics of quality and site performance.A secondary data analysis of the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study was performed. There were 3070 treatment-naive, hepatitis C virus genotype 1 infected patients were included. We retrospectively evaluated rates of screen failure, completion, and discontinuation of treatment and follow-up, treatment adherence, and virologic response by site type.Of the patients screened, 63% and 37% were in academic and community centers, respectively. Screen failure rates were similar (30% to 32%). End-of-treatment response, relapse, and sustained virologic response (SVR) rates in academic and community centers did not differ. SVR was achieved in 40% of patients at academic sites and 39% at community sites. Adherence to ≥80% of peginterferon-α and ribavirin dosing for ≥80% assigned duration was also similar (46% in academic and 47% in community centers). In both academic and community centers, 54% of patients completed treatment; there were similar discontinuation rates for treatment failure and adverse events.There were no significant differences in adherence, adverse events, rates of discontinuation, on-treatment virologic response, and SVR when comparing academic and community sites. The performance of academic-based and experienced community-based sites in clinical trials is largely similar for the treatment of chronic hepatitis C.

Full Text

Duke Authors

Cited Authors

  • Jou, JH; Sulkowski, MS; Noviello, S; Long, J; Pedicone, LD; McHutchison, JG; Muir, AJ

Published Date

  • November 2013

Published In

Volume / Issue

  • 47 / 10

Start / End Page

  • e91 - e95

PubMed ID

  • 23787248

Pubmed Central ID

  • 23787248

Electronic International Standard Serial Number (EISSN)

  • 1539-2031

International Standard Serial Number (ISSN)

  • 0192-0790

Digital Object Identifier (DOI)

  • 10.1097/MCG.0b013e318294baa4


  • eng